Developer docs
API playgroundTry for free, no card

Search company profiles

EnginZyme

Full company profile

uuid0000ub3

Namestring
EnginZyme
Legal namestring
EnginZyme AB
Websiteurl
enginzyme.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell-free biomanufacturing, enzyme immobilization technology, biocatalysis process development, industrial biocatalyst products, mRNA nucleotide manufacturing
Industry4 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Industrial Biotechnology / Biocatalysis
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biocatalyst Products
TypeOne Time License
Description

Sale of turnkey biocatalysts including EziG-CalB and EziG-Lip, as well as specialty ingredients like Pseudouridine (cGMP grade). Products available for off-the-shelf solutions or customized development.

enginzyme.com
2Biocatalysis Services
TypeProfessional Services
Description

Full-stack service offerings including feasibility studies, enzyme discovery and engineering, catalyst development and customization, and process development from lab to pilot scale.

enginzyme.com
3Bespoke Bioprocess Development
TypeProfessional Services
Description

Customized bioprocess development using proprietary platform for efficient, sustainable, and scalable synthesis of molecules. Process development from discovery to scale-up.

enginzyme.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1EziG
Description

World's most efficient enzyme immobilization technology enabling creation of tailored, stable solid biocatalysts for multistep enzymatic reactions.

enginzyme.com
+4 more records
Core offering1 text field

EnginZyme sells a proprietary cell-free biomanufacturing platform built on patented EziG enzyme immobilization technology, offering EziG-CalB and EziG-Lip immobilized biocatalysts for esterification, transesterification, and food oil interesterification, plus cGMP-grade Pseudouridine as a specialty ingredient for mRNA vaccines. The platform is delivered to enterprise customers in food, pharma, cosmetics, and industrial chemicals through both off-the-shelf catalyst/ingredient sales and full-stack services covering feasibility studies, enzyme discovery and engineering, catalyst customization, and lab-to-pilot scale-up.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Energy savings: 0% energy compared with traditional catalysis (referenced on company page as stated metric)
+3 more records
Product overview1 text field

EnginZyme offers a comprehensive product portfolio centered on its proprietary cell-free biomanufacturing platform. The core offering includes EziG® branded biocatalysts (EziG®-CalB for esterification/transesterification reactions and EziG®-Lip for food oil interesterification), plus Pseudouridine as a specialty ingredient for mRNA vaccine manufacturing. These products are complemented by full-service offerings including feasibility studies, enzyme discovery and engineering, and catalyst customization services. The platform enables customers to replace traditional chemical catalysts with enzymes for sustainable manufacturing across cosmetics, food, pharma, and industrial chemicals sectors.

Product and service8 records
1EziG-CalB Biocatalyst
CategoryBiocatalyst Product
Description

Immobilized Candida antarctica lipase B catalyst designed for efficient esterification, transesterification, and amidation reactions, offering high selectivity and stability for sustainable synthesis of cosmetic ingredients, emollients, and specialty esters.

2EziG-Lip Biocatalyst
CategoryBiocatalyst Product
Description

Next-generation immobilized lipase catalyst for batch enzymatic interesterification (bEIE) of fats and oils, enabling sustainable production of high-quality oils and fats without harsh chemicals or unwanted by-products, combining enzymatic interesterification benefits with batch processing flexibility.

3Pseudouridine Specialty Ingredient
CategorySpecialty Ingredient
Description

Critical precursor for mRNA nucleotides and a key ingredient in mRNA COVID-19 vaccines, manufactured under cGMP using a green, scalable enzymatic process with >99 wt.% purity specification (CAS Number 1445-07-4, EC Number 978-484-6).

4Feasibility Study Service
CategoryService Offering
Description

Technical and economic assessment of applying biocatalysis to customer chemistry, providing consultation on enzyme families and early process development with a clear technical path forward and risk/cost briefing.

5Enzyme Discovery and Engineering Service
CategoryService Offering
Description

Service that finds and refines the right enzyme for customer needs, from initial discovery to optimization, delivering a curated panel of wild-type enzyme sequences or targeted in-house enzyme design, screening, and validation.

6EziG Screening and Customization Service
CategoryService Offering
Description

Selection and customization of EziG carrier materials to match customer process requirements, including catalyst development, application testing, automated formulation screening, and cascade optimization for both batch and continuous operations.

7N1-methylpseudouridine-5'-triphosphate (m1PsiTP) Manufacturing Process
CategorySpecialty Ingredient / Manufacturing Process
Description

Scalable hybrid manufacturing process for N1-methylpseudouridine-5'-triphosphate (m1PsiTP), combining selective chemical methylation with a multi-enzyme phosphorylation cascade to deliver a critical mRNA vaccine and therapy ingredient at kilogram scale in an animal-free, cGMP-compliant European facility.

8Cell-Free Biomanufacturing Platform
CategoryPlatform Technology
Description

Proprietary cell-free biomanufacturing platform combining patented EziG enzyme immobilization technology with process engineering for sustainable industrial chemical synthesis, enabling biocatalysis deployment using traditional chemical manufacturing tools without living organisms.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Collaboration to create scalable process for N1-methylpseudouridine-5'-triphosphate (m1PsiTP), a key mRNA vaccine and therapy ingredient. Combines selective chemical methylation with multi-enzyme phosphorylation cascade. Manufacturing planned for Europe, animal-free, cGMP compliant. Kilogram-scale manufacturing targeted for 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-25
Description

CDMO partnership for scale-up and cGMP manufacturing of pseudouridine at industrial scale. Developed patented process to manufacture pseudouridine for mRNA vaccines using biocatalysis. Already synthesized enough pseudouridine for more than 500 million vaccine doses in cGMP-compliant facility.

3Tetra Pak
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-02
Description

Strategic collaboration to bring sustainable and economically sound solutions to food and beverage industry. Companies leveraging respective strengths to find ways to improve food production, such as turning food waste (acid whey) into valuable ingredients. Tetra Pak integrating EnginZyme's biotechnology directly into product or waste-stream lines for easy scaling.

enginzyme.com
4Bunge
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Industry partnership for enzymatic interesterification of food oils. Customizing processes for low-trans or trans-fat-free margarines and shortenings. Working to cut costs and create purer, safer, more sustainable products without extensive downstream processing.

enginzyme.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Codexis engineers novel enzymes and biocatalysts for pharmaceutical and industrial applications using its proprietary CodeEvolver platform. Closest direct peer to EnginZyme given shared focus on protein engineering for sustainable chemical manufacturing and pharma intermediates.

TypeBroad incumbent
Description

Global leader in industrial enzymes with massive scale across food, agriculture, and bioenergy. Competes broadly with EnginZyme in food oil processing and industrial biocatalysis, though focused on secreted bulk enzymes versus EnginZyme's cell-free immobilized approach.

TypeBroad incumbent
Description

Synthetic biology platform company developing engineered organisms and enzymes for industrial customers. Differs in cell-based approach but shares the thesis of biology-as-manufacturing and serves overlapping end markets.

TypeDirect peer
Description

Specialty enzyme producer serving food, beverage, and industrial sectors. Comparable to EnginZyme's EziG-Lip and food oil applications; both supply enzymes as products to industrial processors.

TypeDirect peer
Description

French biotech developing enzymatic processes for plastics recycling and PET depolymerization. Comparable in using engineered enzymes as industrial process catalysts with a sustainability positioning similar to EnginZyme.

6Amano Enzyme
TypeRegional player
Description

Japanese manufacturer of industrial enzymes for food, pharmaceutical, and diagnostic applications. Comparable product portfolio focused on lipases and specialty enzymes but with primary geographic strength in Asia rather than Europe.

TypeBroad incumbent
Description

Diversified ingredients company with significant presence in food, personal care, and nutritional enzymes. Competes with EnginZyme in cosmetic emollients and food oil processing as part of a much broader portfolio.

TypeEmerging player
Description

Synthetic biology startup building a platform for sustainable biomanufacturing of chemicals and ingredients using engineered microbes. Comparable in targeting industrial customers with bio-based process alternatives, though cell-based rather than cell-free.

TypeOthers
Description

Major specialty chemicals and sustainable technologies company with catalyst and process technology divisions (including former CTO's previous employer). Adjacent rather than directly competitive, but represents the traditional catalysis infrastructure EnginZyme aims to displace with biocatalysis.

TypeEmerging player
Description

Computational protein design company offering protein engineering software and services using Rosetta and other tools. Comparable in the AI/ML-driven protein design layer underlying EnginZyme's Thunderdome and Thunder Dream platforms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EnginZyme

Industrial Biotechnology / Biocatalysisenginzyme.com

EnginZyme firmographics

Firmographics
Name
EnginZyme
Legal name
EnginZyme AB
Website
https://enginzyme.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

EnginZyme industry classification

Industry
Product category
Industrial Biotechnology / Biocatalysis
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Cell-free biomanufacturing
  • Enzyme immobilization technology
  • Biocatalysis process development
  • Industrial biocatalyst products
  • MRNA nucleotide manufacturing

Where EnginZyme is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

EnginZyme business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Biocatalyst Products: Sale of turnkey biocatalysts including EziG-CalB and EziG-Lip, as well as specialty ingredients like Pseudouridine (cGMP grade). Products available for off-the-shelf solutions or customized development.
  2. Biocatalysis Services: Full-stack service offerings including feasibility studies, enzyme discovery and engineering, catalyst development and customization, and process development from lab to pilot scale.
  3. Bespoke Bioprocess Development: Customized bioprocess development using proprietary platform for efficient, sustainable, and scalable synthesis of molecules. Process development from discovery to scale-up.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

EnginZyme product offering

Product offering

Core offering

EnginZyme sells a proprietary cell-free biomanufacturing platform built on patented EziG enzyme immobilization technology, offering EziG-CalB and EziG-Lip immobilized biocatalysts for esterification, transesterification, and food oil interesterification, plus cGMP-grade Pseudouridine as a specialty ingredient for mRNA vaccines. The platform is delivered to enterprise customers in food, pharma, cosmetics, and industrial chemicals through both off-the-shelf catalyst/ingredient sales and full-stack services covering feasibility studies, enzyme discovery and engineering, catalyst customization, and lab-to-pilot scale-up.

Product overview

EnginZyme offers a comprehensive product portfolio centered on its proprietary cell-free biomanufacturing platform. The core offering includes EziG® branded biocatalysts (EziG®-CalB for esterification/transesterification reactions and EziG®-Lip for food oil interesterification), plus Pseudouridine as a specialty ingredient for mRNA vaccine manufacturing. These products are complemented by full-service offerings including feasibility studies, enzyme discovery and engineering, and catalyst customization services. The platform enables customers to replace traditional chemical catalysts with enzymes for sustainable manufacturing across cosmetics, food, pharma, and industrial chemicals sectors.

Differentiator

Problem solved

Functional benefit

Brands

  • EziG: World's most efficient enzyme immobilization technology enabling creation of tailored, stable solid biocatalysts for multistep enzymatic reactions.
  • EziG-CalB
  • EziG-Lip
  • Thunderdome
  • Thunder Dream

Products and services

  • EziG-CalB Biocatalyst Immobilized Candida antarctica lipase B catalyst designed for efficient esterification, transesterification, and amidation reactions, offering high selectivity and stability for sustainable synthesis of cosmetic ingredients, emollients, and specialty esters.
  • EziG-Lip Biocatalyst Next-generation immobilized lipase catalyst for batch enzymatic interesterification (bEIE) of fats and oils, enabling sustainable production of high-quality oils and fats without harsh chemicals or unwanted by-products, combining enzymatic interesterification benefits with batch processing flexibility.
  • Pseudouridine Specialty Ingredient Critical precursor for mRNA nucleotides and a key ingredient in mRNA COVID-19 vaccines, manufactured under cGMP using a green, scalable enzymatic process with >99 wt.% purity specification (CAS Number 1445-07-4, EC Number 978-484-6).
  • Feasibility Study Service Technical and economic assessment of applying biocatalysis to customer chemistry, providing consultation on enzyme families and early process development with a clear technical path forward and risk/cost briefing.
  • Enzyme Discovery and Engineering Service Service that finds and refines the right enzyme for customer needs, from initial discovery to optimization, delivering a curated panel of wild-type enzyme sequences or targeted in-house enzyme design, screening, and validation.
  • EziG Screening and Customization Service Selection and customization of EziG carrier materials to match customer process requirements, including catalyst development, application testing, automated formulation screening, and cascade optimization for both batch and continuous operations.
  • N1-methylpseudouridine-5'-triphosphate (m1PsiTP) Manufacturing Process Scalable hybrid manufacturing process for N1-methylpseudouridine-5'-triphosphate (m1PsiTP), combining selective chemical methylation with a multi-enzyme phosphorylation cascade to deliver a critical mRNA vaccine and therapy ingredient at kilogram scale in an animal-free, cGMP-compliant European facility.
  • Cell-Free Biomanufacturing Platform Proprietary cell-free biomanufacturing platform combining patented EziG enzyme immobilization technology with process engineering for sustainable industrial chemical synthesis, enabling biocatalysis deployment using traditional chemical manufacturing tools without living organisms.

Quantifiable outcome

  • Energy savings: 0% energy compared with traditional catalysis (referenced on company page as stated metric)
  • +3 more outcomes

Companies that use EnginZyme

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles4 records

EnginZyme technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature10 records

EnginZyme partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • AGC Inc.coreStrategic or Co-development Partner · 12 January 2026Collaboration to create scalable process for N1-methylpseudouridine-5'-triphosphate (m1PsiTP), a key mRNA vaccine and therapy ingredient. Combines selective chemical methylation with multi-enzyme phosphorylation cascade. Manufacturing planned for Europe, animal-free, cGMP compliant. Kilogram-scale manufacturing targeted for 2026.
  • Ajinomoto Bio-Pharma ServicescoreStrategic or Co-development Partner · 25 October 2023CDMO partnership for scale-up and cGMP manufacturing of pseudouridine at industrial scale. Developed patented process to manufacture pseudouridine for mRNA vaccines using biocatalysis. Already synthesized enough pseudouridine for more than 500 million vaccine doses in cGMP-compliant facility.
  • Tetra PakcoreStrategic or Co-development Partner · 2 June 2022Strategic collaboration to bring sustainable and economically sound solutions to food and beverage industry. Companies leveraging respective strengths to find ways to improve food production, such as turning food waste (acid whey) into valuable ingredients. Tetra Pak integrating EnginZyme's biotechnology directly into product or waste-stream lines for easy scaling.
  • BungecoreStrategic or Co-development PartnerIndustry partnership for enzymatic interesterification of food oils. Customizing processes for low-trans or trans-fat-free margarines and shortenings. Working to cut costs and create purer, safer, more sustainable products without extensive downstream processing.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

EnginZyme competitors and assessment

Company assessment

Direct peers

  • Codexis: Codexis engineers novel enzymes and biocatalysts for pharmaceutical and industrial applications using its proprietary CodeEvolver platform. Closest direct peer to EnginZyme given shared focus on protein engineering for sustainable chemical manufacturing and pharma intermediates.
  • AB Enzymes: Specialty enzyme producer serving food, beverage, and industrial sectors. Comparable to EnginZyme's EziG-Lip and food oil applications; both supply enzymes as products to industrial processors.
  • Carbios: French biotech developing enzymatic processes for plastics recycling and PET depolymerization. Comparable in using engineered enzymes as industrial process catalysts with a sustainability positioning similar to EnginZyme.

Broad incumbents

  • Novonesis (formerly Novozymes): Global leader in industrial enzymes with massive scale across food, agriculture, and bioenergy. Competes broadly with EnginZyme in food oil processing and industrial biocatalysis, though focused on secreted bulk enzymes versus EnginZyme's cell-free immobilized approach.
  • Ginkgo Bioworks: Synthetic biology platform company developing engineered organisms and enzymes for industrial customers. Differs in cell-based approach but shares the thesis of biology-as-manufacturing and serves overlapping end markets.
  • DSM-firmenich: Diversified ingredients company with significant presence in food, personal care, and nutritional enzymes. Competes with EnginZyme in cosmetic emollients and food oil processing as part of a much broader portfolio.

Regional players

  • Amano Enzyme: Japanese manufacturer of industrial enzymes for food, pharmaceutical, and diagnostic applications. Comparable product portfolio focused on lipases and specialty enzymes but with primary geographic strength in Asia rather than Europe.

Emerging players

  • Bota Bio: Synthetic biology startup building a platform for sustainable biomanufacturing of chemicals and ingredients using engineered microbes. Comparable in targeting industrial customers with bio-based process alternatives, though cell-based rather than cell-free.
  • Cyrus Biotechnology: Computational protein design company offering protein engineering software and services using Rosetta and other tools. Comparable in the AI/ML-driven protein design layer underlying EnginZyme's Thunderdome and Thunder Dream platforms.

Others

  • Johnson Matthey: Major specialty chemicals and sustainable technologies company with catalyst and process technology divisions (including former CTO's previous employer). Adjacent rather than directly competitive, but represents the traditional catalysis infrastructure EnginZyme aims to displace with biocatalysis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

EnginZyme social profiles

Digital presence

EnginZyme compliance and trust

Trust signal

Compliance4 records

EnginZyme financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EnginZyme leadership team

Management profile

Number of profiles

Profiles16 records

EnginZyme funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EnginZyme M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EnginZyme

What does EnginZyme do?

EnginZyme sells a proprietary cell-free biomanufacturing platform built on patented EziG enzyme immobilization technology, offering EziG-CalB and EziG-Lip immobilized biocatalysts for esterification, transesterification, and food oil interesterification, plus cGMP-grade Pseudouridine as a specialty ingredient for mRNA vaccines. The platform is delivered to enterprise customers in food, pharma, cosmetics, and industrial chemicals through both off-the-shelf catalyst/ingredient sales and full-stack services covering feasibility studies, enzyme discovery and engineering, catalyst customization, and lab-to-pilot scale-up.

Is EnginZyme a public or private company?

EnginZyme is a private company. It is classified as venture growth investor backed and is currently operating.

When was EnginZyme founded?

EnginZyme was founded in 2014. It employs 11 to 50 people.

Where is EnginZyme based?

EnginZyme is headquartered in Solna, Sweden, in the Europe region.

How does EnginZyme make money?

Three revenue lines are on record. Biocatalyst Products are the primary driver. The others are biocatalysis Services and bespoke Bioprocess Development.

Who are EnginZyme's main competitors?

Direct peers on record are Codexis, AB Enzymes and Carbios. Broad incumbents are Novonesis (formerly Novozymes), Ginkgo Bioworks and DSM-firmenich. Amano Enzyme is listed as a regional player. Emerging players are Bota Bio and Cyrus Biotechnology. Johnson Matthey is listed as an others.

Does EnginZyme have an API?

No public API is recorded for EnginZyme.

What industry is EnginZyme in?

EnginZyme's product category is Industrial Biotechnology / Biocatalysis. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Enginzyme Raises SEK 75 Million To Advance Commercial Biomanufacturing StrategyEnginzyme raised SEK 75 million in new equity financing, with new investors Lotus One Investment and Valquest Partners Europe joining. The Swedish biotech company will use the funds to expand adoption of its cell-free biomanufacturing technology across personal care, food, and pharmaceutical industries.FinSMEsEnginzyme Raises SEK 75M in FundingEnginzyme, a Solna, Sweden-based biomanufacturing platform, raised SEK 75M (about $7.6M) from investors including Lotus One, Valquest, and Sofinnova. The company will use the funds to accelerate its shift from R&D to a commercially driven strategy, delivering biomanufacturing solutions for personal care, food, and pharmaceutical industries.Business Wire BlogEnginzyme Raises SEK 75 Million to Advance Its Commercial Biomanufacturing StrategyEnginzyme AB closed a new equity round raising SEK 75 million, with new shareholders Lotus One Investment and Valquest Partners joining. The round marks a shift from R&D to a commercially driven strategy, with new shareholders contributing expertise to deliver biomanufacturing solutions for personal care, food, and pharmaceutical industries.GrayBiotechnology and Its Impact on ManufacturingThe article outlines the expanding role of biomanufacturing and synthetic biology in enhancing efficiency, reducing costs, and minimizing environmental impact across sectors like pharmaceuticals, consumer products, and agriculture. Key companies including Genomatica, Zymergen, and EnginZyme are highlighted for developing technologies that utilize biological processes to produce materials such as nylon precursors, electronic films, and chemical ingredients with lower energy consumption. The U.S. Department of Defense is also noted for its initiative to establish a Synthetic Biology Manufacturing Innovation Institute to strengthen domestic supply chain security.CleantechCell-Free Biomanufacturing: Decentralized Approach for Fuels & Chemicals SynthesisThe article analyzes the emerging potential of cell-free biomanufacturing as a decentralized, sustainable alternative to traditional fossil-fuel-based chemical production, highlighting its ability to reduce costs and emissions through AI-optimized enzyme systems. Key innovators such as Enginzyme, FabricNano, Solugen, and Ginkgo Bioworks are driving commercialization efforts, with Solugen advancing large-scale manufacturing in the U.S. and strategic partnerships forming across the sector. The report underscores significant geopolitical competition between the U.S. and China, noting substantial government funding like the NSF's $40M CFIRE program to support domestic bioeconomy infrastructure.Labiotech.euThe biggest private biotech investments in December 2022A roundup of the largest private biotech investments in December 2022 identifies multiple companies across healthcare and industrial biotechnology sectors that secured significant funding rounds globally. Apogee Therapeutics led U.S. healthcare biotech with a $149 million Series B round, while Qitan Technology topped the Asia-Pacific industrial biotech rankings with a $100 million Series C round to develop a nanopore-based DNA sequencer. European companies also saw notable funding, including U.K.-based Pulmocide's $52 million Series C and Sweden's EnginZyme's $22.3 million Series B round.FinSMEsEnginZyme Raises €21M in Series B FundingEnginZyme, a Stockholm-based green tech company, raised €21M in Series B funding from investors including Almi Invest GreenTech, Navigare Ventures, and Bunge Ventures. The funds will support large-scale commercialization and new features of its enzyme-based biomanufacturing platform.PR NewswireEnginZyme raises €21 million in Series B to accelerate the commercialisation of its cell-free biomanufacturing technologyEnginZyme raised €21 million in a Series B financing round to accelerate the commercialization of its cell-free biomanufacturing technology. The investment round included new investors Almi Invest GreenTech, Navigare Ventures, and Bunge Ventures joining existing backers Sofinnova Partners, Industrifonden, and SEB GreenTech VC. The company intends to use the funds for large-scale global commercialization and to enhance its proprietary technology platform.BioSpaceEnginZyme Raises €21 Million in Series B to Accelerate the Commercialisation of Its Cell-Free Biomanufacturing TechnologyEnginZyme, a Swedish biomanufacturing company, announced the closing of a €21 million Series B financing round to support the global commercialization of its cell-free technology. New investors including Almi Invest GreenTech, Navigare Ventures, and Bunge Ventures joined existing backers Sofinnova Partners, Industrifonden, and SEB GreenTech VC in the funding. The capital will be used to scale operations and enhance the proprietary platform for sustainable chemical manufacturing.Business Wire BlogEnginZyme Raises €21 Million in Series B to Accelerate the Commercialisation of Its Cell-Free Biomanufacturing TechnologyEnginZyme announced the closing of a €21 million Series B financing round to accelerate the global commercialisation of its cell-free biomanufacturing technology. The investment was led by new backers Almi Invest GreenTech, Navigare Ventures, and Bunge Ventures, joining existing investors Sofinnova Partners, Industrifonden, and SEB GreenTech VC. These funds will be used to scale operations and enhance the company's proprietary enzymatic platform for sustainable manufacturing.